Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

CKD Bio Corp. Logo
Develops APIs, intermediates, and probiotics using fermentation and synthesis.
South Korea
063160
Clearmind Medicine Inc. Logo
Clinical-stage psychedelic pharma firm developing treatments for Alcohol Use Disorder.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Biopharmaceutical firm with an FDA-approved microinjector for back-of-the-eye delivery.
United States of America
CLSD
Clene Inc. Logo
A clinical-stage biopharma developing nanotherapeutics for neurodegenerative diseases.
United States of America
CLNN
CMG Pharmaceutical Co., Ltd. Logo
A pharmaceutical firm specializing in Oral Thin Film drug delivery technology.
South Korea
058820
CNS Pharmaceuticals, Inc. Logo
Develops anti-cancer drug candidates for cancers of the brain and nervous system.
United States of America
CNSP
Cocrystal Pharma, Inc. Logo
Clinical-stage biotech developing antiviral drugs for serious and chronic viral diseases.
United States of America
COCP
Co-Diagnostics, Inc. Logo
A molecular diagnostics company that develops and markets advanced PCR technologies.
United States of America
CODX
co.don AG Logo
Develops autologous cell therapies for regenerative treatment of cartilage defects.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Biopharmaceutical company developing cell therapy platforms for cancer and other diseases.
United States of America
COEP

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.